Completed PHASE2 INTERVENTIONAL 4-arm NCT01705223

Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)

Phase IIa Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)

Sponsor: National Center for AIDS/STD Control and Prevention, China CDC

Conditions AIDS

Interventions DNA vaccine DNA vaccine prime with the addition of electroporation rTV boost

Updated 5 times since 2017 Last updated: May 5, 2015 Started: Aug 31, 2012 Primary completion: Oct 31, 2014 Completion: Jan 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01705223, this PHASE2 trial focuses on AIDS and remains completed. Sponsored by National Center for AIDS/STD Control and Prevention, China CDC, it has been updated 5 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Center for AIDS/STD Control and Prevention, China CDC

Data source: National Center for AIDS/STD Control and Prevention, China CDC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China